索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]夏丽娟,陈书艳.高尿酸血症和心房颤动的相关性研究进展[J].国际心血管病杂志,2023,01:38-40.
点击复制

高尿酸血症和心房颤动的相关性研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年01期
页码:
38-40
栏目:
综述
出版日期:
2023-01-20

文章信息/Info

Title:
-
作者:
夏丽娟; 陈书艳
200025 上海交通大学医学院（夏丽娟）； 200092 上 海交通大学医学院附属新华医院老年医学科（陈书艳）
Author(s):
-
关键词:
高尿酸血症; 心房颤动; 血清尿酸
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.01.010
文献标识码:
-
摘要:
尿酸是氧化损伤和炎性反应的生物标志物，高尿酸血症与心房颤动有关。高尿 酸血症可能通过炎性反应和氧化应激参与了心房重构。该文介绍高尿酸血症与心房颤动的 发生、进展及复发之间的相关性，并探讨降尿酸治疗对心房颤动的影响，为心房颤动的上游 治疗提供思路。
Abstract:
-

参考文献/References

[1] Dai HJ, Zhang QY, Much AA, et al. Global, regional, and National prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017[J]. Eur Heart J Qual Care Clin Outcomes, 2021, 7(6):574-582.
[2] Lin WD, Deng H, Guo P, et al. High prevalence of hyperuricaemia and its impact on non-valvular atrial fibrillation: the cross-sectional Guangzhou (China) Heart Study[J]. BMJ Open, 2019, 9(5):e028007.
[3] Li SS, Cheng J, Cui LF, et al. Cohort study of repeated measurements of serum urate and risk of incident atrial fibrillation[J]. J Am Heart Assoc, 2019, 8(13):e012020.
[4] Kawasoe S, Kubozono T, Yoshifuku S, et al. Uric acid level and new-onset atrial fibrillation in the Japanese general population - longitudinal study[J]. Circ J, 2018, 83(1):156- 163.
[5] Kuwabara M, Niwa K, Nishihara S, et al. Hyperuricemia is an Independent competing risk factor for atrial fibrillation[J]. Int J Cardiol, 2017, 231:137-142.
[6] Wang XH, Hou YL, Wang XM, et al. Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis[J]. Nutr Metab Cardiovasc Dis, 2021, 31(10):2756-2765.
[7] Zhang X, Hu MJ, Wang XY, et al. New perspective on the risk markers for left atrial thrombosis in patients with atrial fibrillation[J]. Eur J Prev Cardiol, 2021, 28(6):641-647.
[8] Liu FZ, Liao HT, Lin WD, et al. Predictive effect of hyperuricemia on left atrial stasis in non-valvular atrial fibrillation patients[J]. Int J Cardiol, 2018, 258:103-108.
[9] 徐海霞, 陆齐, 黄荫浩, 等. 阵发性心房颤动患者射频消 融术后复发的预测因素分析[J]. 中国循环杂志, 2017, 32(12):1203-1207.
[10] Zhao JP, Liu T, Korantzopoulos P, et al. Association between serum uric acid and atrial fibrillation recurrence following catheter ablation: a meta-analysis[J]. Int J Cardiol, 2016, 204:103-105.
[11] Nam JH, Park KH, Lee JH, et al. Discordant relationships between systemic inflammatory markers and burden of oxidative stress in patients with atrial fibrillation[J]. Korean Circ J, 2017, 47(5):752-761.
[12] Zacharia E, Papageorgiou N, Ioannou A, et al. Inflammatory biomarkers in atrial fibrillation[J]. Curr Med Chem, 2019, 26(5):837-854.
[13] Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis[J]. Int J Mol Sci, 2021, 22(22):12394.
[14] Milanesi S, Verzola D, Cappadona F, et al. Uric acid and angiotensin Ⅱ additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll-like receptor 4[J]. J Cell Physiol, 2019, 234(7):10868-10876.
[15] Wang DY, Sun L, Zhang GW, et al. Increased susceptibility of atrial fibrillation induced by hyperuricemia in rats: mechanisms and implications[J]. Cardiovasc Toxicol, 2021, 21(3):192-205.
[16] Maharani N, Ting YK, Cheng JD, et al. Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes[J]. Circ J, 2015, 79(12):2659-2668.
[17] Fang DH, Wang N, Chen QF, et al. The association between hyperuricemia and left atrial enlargement in healthy adults[J]. Ann Transl Med, 2021, 9(14):1176.
[18] Sun HL, Wu YW, Bian HG, et al. Function of uric acid transporters and their inhibitors in hyperuricaemia[J]. Front Pharmacol, 2021, 12:667753.
[19] Hong M, Park JW, Yang PS, et al. A mendelian randomization analysis: the causal association between serum uric acid and atrial fibrillation[J]. Eur J Clin Invest, 2020, 50(10):e13300.
[20] Singh JA, Yu SH. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data[J]. Ann Rheum Dis, 2017, 76(1):72-78.
[21] Singh JA, Cleveland JD. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data[J]. Eur Heart J, 2019, 40(36):3046-3054.
[22] Xu DZ, Murakoshi N, Tajiri K, et al. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKⅡ in Dahl salt-sensitive rats[J]. Clin Sci (Lond), 2021, 135(20):2409-2422.

备注/Memo

备注/Memo:
通信作者：陈书艳，E-mail：chenshuyan@xinhuamed.com.cn
更新日期/Last Update: 2023-01-20